In the IL-18 and TK/GCV combination gene therapy group, infiltration of CD4+ T cells at the injection site of IL18-TK52 cells (Fig. 5A) indicated that the local pre-treatment of IL-18 might maintain the T-lymphocyte status around the tumor. The gene discussed is CD4; the disease is neoplasm.